Deerfield Management Company, L.P. (Series C) Pep Gen Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$9.31 - $16.57 $6.38 Million - $11.4 Million	-685,284 Reduced 91.95%	60,009 $802,000
Q3 2022 Nov 14, 2022	SELL	$4.86 - $12.75 $1.01 Million - $2.66 Million	-208,333 Reduced 21.85%	745,293 $6.77 Million
Q2 2022 Aug 15, 2022	BUY	$9.0 - $12.89 $8.58 Million - $12.3 Million	953,626 New	953,626 $9.47 Million

Others Institutions Holding PEPG

# of Institutions

Shares Held

25.2M

Call Options Held

Put Options Held

Ra Capital Management, L.P. Boston, MA

10.7M
Shares

$38.8 Million
1.27% of portfolio
Janus Henderson Group PLC London, X0

2.34M
Shares

$8.48 Million
0.01% of portfolio
Suvretta Capital Management, LLC New York, NY

1.66M
Shares

$6.03 Million
0.56% of portfolio
Viking Global Investors LP

1.48M
Shares

$5.38 Million
0.05% of portfolio
Perceptive Advisors LLC New York, NY

1.41M
Shares

$5.12 Million
0.32% of portfolio

View Full List

About PepGen Inc.

Ticker PEPG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,631,900
Market Cap $85.8M
Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...

More about PEPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account